Epinephrine-Associated Tachycardia in a 10-Year-Old Girl
Epinephrine administration in anaphylaxis is associated with increased heart rate and should prompt reassessment for persistent or worsening anaphylaxis rather than immediate discontinuation of epinephrine. [1,2] If the tachycardia represents a clinically significant tachyarrhythmia (eg, supraventricular tachycardia) with instability, pediatric advanced life support (PALS) tachyarrhythmia treatment is recommended. [3]
Immediate Patient Assessment
Cardiovascular status should be assessed immediately, including blood pressure, perfusion, mental status, and heart rhythm. [1] Oxygenation and respiratory status should be assessed because respiratory failure from anaphylaxis can drive tachycardia. [1] Continuous monitoring of heart rate and rhythm should be performed during acute management. [1]
Management When Tachycardia Reflects Ongoing Anaphylaxis Physiology
Epinephrine remains first-line therapy for anaphylaxis, and tachycardia alone is not an indication to stop epinephrine. [1,2] At frequent intervals, repeated evaluation of heart rate and rhythm, blood pressure, perfusion, and respiratory and mental status is recommended. [1] If cardiovascular compromise is present, intravenous fluids should be administered for cardiovascular instability. [1]
Management When Tachycardia Represents a Treatable Tachyarrhythmia
If electrocardiographic rhythm confirms supraventricular tachycardia or another tachyarrhythmia requiring specific antiarrhythmic therapy, PALS tachyarrhythmia algorithms should be followed. [3] Unstable tachyarrhythmia should be managed with immediate electrical cardioversion per PALS pathways. [3] Stable narrow-complex tachyarrhythmia should be managed with PALS-supported pharmacologic therapy per the tachyarrhythmia algorithm. [3]
Medication Adjustment for Cathecholamine Excess Without Instability
For isolated sinus tachycardia that is temporally associated with epinephrine and without clinical instability, management should focus on supportive care and reassessment of ongoing anaphylaxis features. [1] Additional epinephrine dosing should be guided by the clinical status of anaphylaxis rather than heart rate alone. [1,2]
Use of Beta-Blockers in Epinephrine-Induced Tachycardia
Beta-blocker use can reduce the physiologic response to epinephrine in patients with anaphylaxis, and the presence of persistent anaphylaxis physiology should remain the dominant management target. [1,2] Parenteral glucagon may be required for patients on beta-blockers with poor response to epinephrine in refractory anaphylaxis. [1]
Monitoring and Disposition
Ongoing monitoring of heart rate and rhythm should continue after treatment because recurrence or progression can occur. [1] Disposition should be based on resolution of anaphylaxis signs, stabilization of cardiovascular and respiratory status, and the absence of recurrent symptoms during observation periods recommended by anaphylaxis guidance. [1,2]
Common Pitfalls to Avoid
Tachycardia should not be treated as an indication for stopping epinephrine when anaphylaxis features persist. [1,2] A rhythm that is treated as “epinephrine-induced” should be confirmed as sinus tachycardia; tachyarrhythmias require PALS-directed therapy. [3]
Targets of Therapy
Clinical targets should include normalization of perfusion and blood pressure and stabilization of respiratory status. [1] Heart rate reduction should not be the primary therapeutic target when anaphylaxis physiology is present; resolution of anaphylaxis and restoration of physiologic stability should guide therapy. [1,2]